A Safety Study of Brentuximab Vedotin in Participants With HIV

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study will test brentuximab vedotin to see if it is safe for people with human immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART) treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side effects of this drug as well. A side effect is anything a drug does to the body besides treating the disease. In this study participants will be assigned randomly to a group. Participants will get either brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any medicine in it. All participants will keep getting ART during the study.
Epistemonikos ID: 570163fe018b5be08f8069611ea9f772baa50733
First added on: May 10, 2024